
101 Therapeutics Presents Positive Phase 2/3 Data for Macrophage-Targeted 101-PGC-005 at ACR 2026
101 Therapeutics Presents Phase 2/3 Clinical Data for CD206-Targeted Therapy 101-PGC-005 at ACR Convergence 2026 101 Therapeutics Ltd., a clinical-stage biotechnology company focused on developing macrophage-targeted therapeutics for inflammatory and…














